| 董世龙,赵莹,赵春辉,等.胃癌靶点 Claudin 18.2的研究进展[J].安徽医药,2023,27(5):884-887. |
| 胃癌靶点 Claudin 18.2的研究进展 |
| Research progress on gastric cancer targeting Claudin 18.2 |
| |
| DOI：10.3969/j.issn.1009-6469.2023.05.008 |
| 中文关键词: 胃肿瘤 受体，表皮生长因子 靶向治疗 Claudin18.2 综述 |
| 英文关键词: Stomach neoplasms Receptor, epidermal growth factor Targeted therapy Claudin18.2 Review |
| 基金项目: |
|
| 摘要点击次数: 737 |
| 全文下载次数: 316 |
| 中文摘要: |
| 我国胃癌的早期诊断率低，大多数病人就诊时已为晚期，失去了根治性手术的机会。晚期胃癌目前以化疗药物治疗为主，但化疗药物具有选择性低、毒副作用大等缺点。随着分子生物学的进展，靶向药物对胃癌的治疗展现出了良好的前景，成为晚期胃癌治疗新的选择。目前，对胃癌有成效的靶向治疗以抗人表皮生长因子受体 -2(HER-2)药物为主，抗血管内皮生长因子药物及免疫检查点抑制剂对胃癌的治疗也取得了一定的成效。近年来， Claudin18.2靶点成为最具前景的胃癌治疗性靶点。该研究针对 Claudin18.2的研究进展展开综述。 |
| 英文摘要: |
| The early diagnosis rate of gastric cancer in China is low, and most patients are already at an advanced stage when theyare diagnosed, which directly leads them to lose the opportunity for radical surgery. At present, chemotherapy is the main treatment foradvanced gastric cancer, but it has the disadvantages of low selectivity and high toxic side effects. With the development of molecularbiology, targeted drugs have shown good prospects for the treatment of gastric cancer and become a new option for the treatment of ad-vanced gastric cancer. At present, the effective targeted therapies for gastric cancer are mainly anti-human epidermal growth factor re-ceptor-2 (HER-2), and anti-vascular endothelial growth factor drugs and immune checkpoint inhibitors have also achieved certain re-sults in the treatment of gastric cancer. In recent years, claudin 18.2 has become the most promising therapeutic target for gastric can-cer. This research reviews the research progress of claudin 18.2. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
